A tacrolimus blood test measures the amount of tacrolimus in whole blood so a transplant team can keep the dose strong enough to prevent rejection but low enough to reduce toxicity. Tacrolimus is a powerful immunosuppressant used after kidney, liver, heart, lung, pancreas, and other organ transplants. It has a narrow therapeutic range, which means small changes in dose, timing, digestion, genetics, or interacting medicines can cause a meaningful change in the blood level.
Most tacrolimus monitoring uses a trough level, drawn right before the next dose. A result is not interpreted like a simple “normal” or “abnormal” screening test. The right target depends on the transplanted organ, time since transplant, rejection risk, infection risk, formulation, lab method, and the rest of the person’s blood work. A single number can be useful, but the trend over time is often more important.
- Tacrolimus is usually measured as a whole-blood trough level in ng/mL, drawn just before the next dose.
- Many transplant targets fall roughly between 5 and 15 ng/mL, but the correct range is individualized.
- Levels above the intended target, especially persistent levels above about 15–20 ng/mL, raise concern for toxicity.
- Tacrolimus toxicity can affect the kidneys, potassium, magnesium, blood pressure, blood sugar, nerves, and infection risk.
- Low tacrolimus levels can increase rejection risk, especially early after transplant or after missed doses.
- Do not change tacrolimus dosing on your own; dose changes should come from the transplant or prescribing team.
Table of Contents
- What the Tacrolimus Blood Test Measures
- Tacrolimus Therapeutic Range and Target Trough Levels
- High Tacrolimus Levels and Toxicity
- Low Tacrolimus Levels and Rejection Risk
- Timing, Preparation, and Why the Trough Matters
- Why Tacrolimus Levels Change
- How Doctors Interpret Tacrolimus Results With Other Tests
- Follow-Up, Dose Changes, and Questions to Ask
What the Tacrolimus Blood Test Measures
The tacrolimus blood test measures how much tacrolimus is circulating in whole blood at the time the sample is drawn. Tacrolimus is not tested mainly to diagnose a disease. It is tested to guide dosing, reduce rejection risk, and catch possible toxicity before serious harm develops.
Tacrolimus belongs to a class of medicines called calcineurin inhibitors. It reduces T-cell activation, which helps stop the immune system from attacking a transplanted organ. Because it suppresses immune activity, too little drug may allow rejection, while too much may cause kidney injury, neurologic symptoms, high potassium, high blood pressure, infections, and other complications.
The test is usually reported in:
- ng/mL, which means nanograms per milliliter
- mcg/L, which is numerically the same as ng/mL
A tacrolimus level of 8 ng/mL is the same concentration as 8 mcg/L.
Tacrolimus is measured in whole blood rather than serum because much of the drug is inside red blood cells. This is one reason the result can be affected by anemia, hematocrit changes, lab method, and transplant-specific targets. Two people can have the same tacrolimus number but different clinical situations.
Therapeutic drug monitoring, not a routine screening test
Tacrolimus testing is a form of therapeutic drug monitoring. The purpose is to match the blood level to a treatment target. This is different from a standard reference range used for tests such as sodium or hemoglobin.
A standard blood test may ask, “Is this value inside the expected range for most healthy people?” Tacrolimus monitoring asks, “Is this drug level right for this person at this time?”
That timing matters. A person one week after a kidney transplant may need a higher tacrolimus target than the same person several years later. A person with recent rejection may need a different target than someone with a serious infection. A person taking a strong interacting antifungal may need a much lower dose to reach the same blood level.
Tacrolimus monitoring often sits beside other transplant and medication tests. For example, it may be interpreted with creatinine, eGFR, potassium, magnesium, liver enzymes, glucose, blood pressure, and symptoms. When kidney function changes while tacrolimus is being adjusted, a focused review such as tacrolimus and creatinine monitoring can help explain the pattern.
Tacrolimus Therapeutic Range and Target Trough Levels
Tacrolimus does not have one universal therapeutic range. Many lab reports show a broad range, often around 5–20 ng/mL, but transplant teams usually use narrower targets based on organ type and time after transplant.
A common pattern is higher targets early after transplant, then lower targets once the organ is stable. Early after transplant, the immune system is more likely to attack the new organ, so stronger immunosuppression may be needed. Later, many patients can be maintained at lower trough levels to reduce long-term toxicity.
The table below gives general examples. These are not personal dosing instructions.
| Clinical situation | Common trough target pattern | How to interpret it |
|---|---|---|
| Early kidney transplant | Often about 8–12 ng/mL, sometimes higher or lower by center | Targets are usually higher during the early rejection-risk period. |
| Stable kidney transplant maintenance | Often about 4–8 or 5–10 ng/mL | Lower long-term targets may reduce kidney and metabolic toxicity. |
| Early liver transplant | Often about 6–12 or 8–15 ng/mL | Targets vary because liver function also affects tacrolimus metabolism. |
| Stable liver transplant maintenance | Often about 3–8 or 5–10 ng/mL | Lower targets are common when graft function is stable. |
| Heart or lung transplant | Often higher early, such as about 10–15 ng/mL, then lower later | Targets depend strongly on time since transplant and rejection history. |
| Recent rejection or high immunologic risk | May be temporarily higher | The transplant team may raise the target while balancing infection and toxicity risk. |
| Serious infection, cancer risk, or toxicity concern | May be intentionally lower | The target may be reduced to avoid excessive immune suppression or organ injury. |
These ranges overlap because transplant care is individualized. A “good” tacrolimus level for one person may be too low or too high for another.
Why the range on the lab report may not be your actual target
The lab report may print a broad therapeutic range because the laboratory does not know every detail of the transplant plan. The transplant clinician usually sets the target.
For example, a report may flag 4 ng/mL as low if the printed range starts at 5 ng/mL. But if the patient is several years after transplant, has stable organ function, and the transplant team’s target is 3–5 ng/mL, that result may be acceptable. The opposite can also happen. A level of 9 ng/mL may sit inside the lab’s printed range but still be high for a patient whose long-term target is 4–6 ng/mL.
The most useful target is usually written in the transplant plan, clinic note, or dosing message. It may look like “goal trough 6–8” or “target tacrolimus 5–7.”
Peak levels are less common than trough levels
Most routine tacrolimus monitoring uses trough levels. A trough is the lowest expected concentration before the next dose. It is easier to compare across visits because it is tied to a specific dosing time.
Peak levels are not commonly used for routine tacrolimus care. Tacrolimus absorption is variable, and the peak may shift depending on food, gut function, formulation, and drug interactions. In special situations, a transplant pharmacologist or specialist may look at more detailed exposure measures, but most patients are managed with trough monitoring plus clinical information.
For readers comparing tacrolimus with other drug-level tests, a broader therapeutic drug monitoring panel can include medicines that are followed by troughs, peaks, or timed post-dose levels depending on the drug.
High Tacrolimus Levels and Toxicity
A high tacrolimus level means the blood concentration is above the intended target for that person. It does not always mean poisoning, but it deserves attention because tacrolimus has a narrow safety margin.
There is no single toxic cutoff that applies to everyone. Toxicity can occur within a “therapeutic” range, especially in sensitive patients, and some people may have a high number without obvious symptoms at first. Even so, persistent trough levels above about 15–20 ng/mL usually raise concern, and levels above 20 ng/mL are often treated as significantly high unless there is a special reason for that target.
The risk depends on:
- How high the level is
- How long it has been high
- Kidney function and urine output
- Potassium and magnesium levels
- Neurologic symptoms
- Blood pressure and blood sugar
- Interacting medicines
- Time since transplant
- Recent rejection or infection
- The person’s usual tacrolimus trend
Common signs and lab patterns of tacrolimus toxicity
Tacrolimus toxicity often shows up through kidney, electrolyte, nerve, and blood pressure changes.
Possible findings include:
- Rising creatinine or falling eGFR
- High potassium
- Low magnesium
- Tremor, shakiness, headache, or insomnia
- Numbness, tingling, burning sensations, or confusion
- High blood pressure
- High blood sugar or new diabetes after transplant
- Nausea, diarrhea, or poor appetite
- Increased infection risk from excessive immune suppression
- Rare severe neurologic problems such as seizures or posterior reversible encephalopathy syndrome
- Rare blood vessel injury patterns such as thrombotic microangiopathy
Kidney effects are especially important because tacrolimus can narrow blood flow in the kidney’s small vessels and cause direct kidney stress. This may happen even when the transplanted organ is not a kidney. A liver, heart, or lung transplant patient can still develop tacrolimus-related kidney injury.
Electrolyte changes can also matter. High potassium can affect heart rhythm, and low magnesium can worsen tremor, muscle cramps, and rhythm risk. If potassium is high along with a high tacrolimus level, the result should be handled promptly. A separate potassium and creatinine pattern can help explain why transplant teams often review these markers together.
When a high level needs urgent attention
A high tacrolimus level should be discussed with the transplant or prescribing team, especially if the result is clearly above the target. Urgent medical advice is important when a high level occurs with:
- Confusion, seizure, severe headache, vision changes, or fainting
- Very high blood pressure or chest pain
- Markedly reduced urination
- Rapidly rising creatinine
- Potassium that is high or rising
- Severe vomiting or diarrhea
- Signs of infection such as fever, chills, shortness of breath, or worsening weakness
Tacrolimus should not be stopped suddenly unless a clinician gives that instruction. Abruptly stopping or skipping doses can place the transplanted organ at risk. In many cases, the team may hold one dose, lower the dose, repeat the level, review timing, and check kidney and electrolyte tests. The exact response depends on the full situation.
Low Tacrolimus Levels and Rejection Risk
A low tacrolimus level means the blood concentration is below the intended target. The main concern is under-immunosuppression, especially early after transplant or in someone with a history of rejection.
A low level does not prove rejection is happening. It means the protective drug exposure may be lower than planned. The team usually looks at the result alongside organ function, symptoms, biopsy results when relevant, donor-specific antibody testing, other immunosuppressant medicines, and the pattern of previous levels.
Common reasons for a low tacrolimus level include:
- A missed or delayed dose
- Taking the dose after the blood draw later than expected
- Blood drawn too late after the last dose
- Vomiting after a dose
- A recent dose reduction
- Switching formulations without correct conversion
- Taking tacrolimus with food inconsistently
- Drug interactions that speed tacrolimus metabolism
- Herbal products such as St. John’s wort
- CYP3A5 expresser genetics, which can make some people clear tacrolimus faster
- Lab or documentation errors involving dose time or draw time
Some medicines can lower tacrolimus levels by increasing CYP3A activity. Examples include rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital, and some other enzyme-inducing drugs. These combinations require close transplant-team oversight.
Low level plus abnormal organ tests
A low tacrolimus level becomes more concerning when organ function is also changing. In a kidney transplant patient, rising creatinine, protein in urine, reduced urine output, or new donor-specific antibodies may prompt more evaluation. In a liver transplant patient, rising liver enzymes or bilirubin may raise concern. In a heart or lung transplant patient, symptoms and organ-specific testing matter.
Low levels are also taken seriously in the first weeks to months after transplant, when the immune system is often most active against the graft. A single mildly low trough may lead to a small dose adjustment and repeat test. A very low or repeatedly low trough may trigger a deeper review of dosing, adherence, interactions, absorption, and rejection risk.
Why “just take more” is unsafe
Tacrolimus dosing should be adjusted by the transplant or prescribing team. Taking extra doses can overshoot the target and cause toxicity. Because tacrolimus levels can rise sharply with certain foods, illness, or interacting medicines, a self-directed increase can become dangerous within days.
A low level is most useful when paired with accurate timing information. The team may ask:
- What time was the last dose?
- What time was the blood drawn?
- Was the morning dose taken before or after the draw?
- Were any doses missed?
- Did vomiting or diarrhea occur?
- Were any new medicines, antibiotics, antifungals, seizure medicines, or supplements started?
- Did the tacrolimus formulation change?
Clear answers often explain the result without needing a major dose change.
Timing, Preparation, and Why the Trough Matters
Tacrolimus timing is one of the most important parts of the test. Most levels should be drawn as a trough, right before the next scheduled dose.
For twice-daily immediate-release tacrolimus, the usual trough is about 12 hours after the last dose. For once-daily extended-release tacrolimus, the usual trough is about 24 hours after the last dose. The exact plan should follow the transplant center’s instructions.
A typical morning blood draw works like this:
- Take the evening dose at the usual time the night before.
- Do not take the morning tacrolimus dose before the blood draw unless the transplant team specifically says to.
- Have the blood drawn close to the scheduled dosing time.
- Take the morning dose after the sample is collected.
- Record the last dose time, blood draw time, dose amount, and formulation.
This process allows the clinician to compare the result with the intended trough target. If the blood is drawn too early or too late, the number may look falsely high or falsely low.
Examples of timing problems
Suppose a person takes tacrolimus at 8 p.m. and has blood drawn at 8 a.m. before the morning dose. That is a 12-hour trough and is usually easy to interpret.
If the same person has blood drawn at 6 a.m., the level may be higher than a true trough because only 10 hours have passed. If the sample is drawn at 11 a.m., the level may be lower because 15 hours have passed. Neither result is useless, but the team needs the timing to interpret it.
Another common problem is taking the morning dose before the blood draw. This can produce a higher post-dose level that may be mistaken for toxicity if the timing is not documented. When that happens, the team may repeat the test rather than make a major dose change.
Food, formulation, and consistency
Tacrolimus absorption can change with food, especially high-fat meals. Many transplant programs advise taking tacrolimus the same way each day, either consistently with food or consistently without food, depending on the plan. The main point is consistency.
Formulation also matters. Tacrolimus products are not automatically interchangeable. Immediate-release tacrolimus, once-daily extended-release tacrolimus, and other formulations may produce different exposure patterns. A person should not switch brands, release forms, or schedules without transplant-team guidance. After a switch, repeat trough monitoring is usually needed.
Why Tacrolimus Levels Change
Tacrolimus levels can change even when the dose stays the same. This is one reason regular monitoring matters.
The body mainly processes tacrolimus through CYP3A enzymes in the liver and intestine, especially CYP3A4 and CYP3A5, and through drug transport systems such as P-glycoprotein. Anything that changes these pathways can change the blood level.
Common causes of higher tacrolimus levels include:
- Azole antifungals such as fluconazole, voriconazole, posaconazole, and itraconazole
- Macrolide antibiotics such as clarithromycin and erythromycin
- Some calcium channel blockers such as diltiazem and verapamil
- Amiodarone
- Some HIV and hepatitis C antiviral regimens
- Grapefruit, pomelo, Seville orange, and related products
- Diarrhea or intestinal inflammation
- Worsening liver function
- Some genetic slow-metabolizer patterns
- Accidental double dosing
Common causes of lower tacrolimus levels include:
- Missed doses
- Delayed doses
- Vomiting soon after taking the medicine
- Rifampin or rifabutin
- Certain seizure medicines such as carbamazepine, phenytoin, and phenobarbital
- St. John’s wort
- Some genetic fast-metabolizer patterns
- Inconsistent use with meals
- Incorrect conversion after a formulation change
Diarrhea deserves special mention because many people assume diarrhea lowers drug absorption. With tacrolimus, diarrhea can sometimes raise levels, partly by changing intestinal metabolism and transport. A transplant patient with diarrhea should contact the transplant team, especially if symptoms are severe, persistent, or accompanied by dehydration, fever, or kidney-test changes.
Genetics and tacrolimus dose needs
Some people need higher or lower tacrolimus doses because of CYP3A5 genetics. People who express functional CYP3A5 often clear tacrolimus faster and may need a higher dose to reach the same trough. People who do not express functional CYP3A5 often need lower doses.
Genetics can help explain dose requirements, but it does not replace blood monitoring. Tacrolimus dosing still depends on measured trough levels, organ function, interactions, time after transplant, and clinical response.
Hematocrit and lab method
Tacrolimus binds heavily within red blood cells. Changes in hematocrit can affect the whole-blood concentration, even when the active unbound drug exposure may not change in the same way. This is one reason anemia, early post-transplant recovery, bleeding, transfusion, and inflammation can complicate interpretation.
Lab method also matters. Some labs use immunoassays, while others use liquid chromatography-tandem mass spectrometry. Immunoassays may measure tacrolimus plus some metabolites and can sometimes read slightly higher than more specific methods. Transplant centers usually interpret results in the context of the lab method they use most often.
How Doctors Interpret Tacrolimus Results With Other Tests
Tacrolimus results are rarely interpreted alone. The same level can mean different things depending on kidney function, liver function, electrolytes, symptoms, infection status, and rejection risk.
A useful interpretation usually includes four questions:
- Was the sample drawn at the correct trough time?
- Is the result inside this person’s current target range?
- Are there signs of toxicity, rejection, infection, or poor absorption?
- Has anything changed, such as a new medicine, illness, missed dose, or formulation switch?
Kidney markers are central because tacrolimus can cause kidney stress and because kidney transplant patients are monitored closely for rejection. Creatinine and eGFR help show whether kidney filtration has changed. A kidney function blood test panel may also include BUN and electrolytes that help clarify dehydration, drug effects, and kidney injury patterns.
Liver markers matter because liver function affects tacrolimus metabolism. If liver function worsens, tacrolimus may build up even without a dose change. In liver transplant patients, liver enzymes and bilirubin also help assess graft function, bile duct problems, rejection, infection, and medication effects.
Electrolytes are reviewed because tacrolimus can raise potassium and lower magnesium. Glucose is often checked because tacrolimus can contribute to high blood sugar or diabetes after transplant. Blood pressure readings are also important because tacrolimus can worsen hypertension.
Result patterns and what they may suggest
| Pattern | Possible meaning | Common next step |
|---|---|---|
| In target, organ tests stable | Current dose may be appropriate | Continue routine monitoring unless symptoms or changes occur. |
| High trough, creatinine rising | Possible tacrolimus nephrotoxicity, dehydration, rejection, or another kidney stressor | Review timing, medicines, fluids, potassium, urine findings, and repeat testing. |
| High trough, tremor or headache | Possible neurologic tacrolimus toxicity | Contact the transplant team; urgent care if severe neurologic symptoms occur. |
| Low trough, stable organ tests | Possible missed dose, late draw, interaction, or need for dose adjustment | Confirm timing and adherence; repeat or adjust dose as instructed. |
| Low trough, organ tests worsening | Possible under-immunosuppression or rejection, among other causes | Prompt transplant-team review and possible additional testing. |
| Sudden unexpected change | Often due to timing, interaction, illness, or formulation change | Check dose history, new medicines, food changes, and sample timing. |
Tacrolimus can also be interpreted with blood counts when infection, bone marrow suppression, or other immunosuppressant effects are being considered. A complete blood count does not measure tacrolimus, but it can show white blood cell, hemoglobin, and platelet patterns that matter in transplant care.
Follow-Up, Dose Changes, and Questions to Ask
Tacrolimus monitoring is most frequent early after transplant and becomes less frequent as the patient stabilizes. Early on, levels may be checked several times per week. Later, stable patients may be checked every few weeks or months, depending on the transplant program.
Extra testing is common after:
- Starting or stopping an interacting medicine
- Changing tacrolimus dose
- Switching tacrolimus formulation or brand
- Vomiting, diarrhea, dehydration, or poor appetite
- Worsening kidney or liver tests
- New tremor, confusion, seizure, severe headache, or high blood pressure
- Rejection treatment
- Major infection
- Pregnancy or major weight and blood-count changes
- Concerns about missed doses or absorption
Dose changes are usually made in small steps because tacrolimus can shift quickly. After a change, the team may recheck the trough after a few days or at the next planned interval. The timing depends on urgency, current level, kidney function, symptoms, and how large the dose change was.
Questions that make a tacrolimus result easier to understand
Good questions for the transplant team include:
- What is my current tacrolimus target trough?
- Is this target temporary or long term?
- Was my blood draw timed correctly?
- Should I take tacrolimus before or after labs?
- Do any of my new medicines interact with tacrolimus?
- Are grapefruit, pomelo, Seville orange, or herbal supplements unsafe for me?
- Do my creatinine, potassium, magnesium, glucose, or blood pressure suggest toxicity?
- Does this result change my rejection risk?
- When should I repeat the level?
- What symptoms should make me call urgently?
Patients who use pill boxes, phone alarms, medication lists, and written dose schedules often have fewer timing problems. Tacrolimus doses can be small and may involve different capsule strengths, so written instructions help prevent accidental extra doses or missed changes.
How to avoid common tacrolimus monitoring mistakes
The most common mistakes are practical ones:
- Taking the morning dose before a trough draw
- Forgetting the exact time of the last dose
- Not reporting missed or late doses
- Starting antibiotics, antifungals, seizure medicines, or supplements without checking interactions
- Eating grapefruit or related citrus products
- Switching formulations without transplant-team approval
- Assuming the lab’s printed range is the same as the personal transplant target
- Changing the dose without instructions
- Ignoring diarrhea because the tacrolimus dose did not change
Tacrolimus monitoring works best when the patient, transplant team, local lab, pharmacy, and primary clinician all use the same medication list and dosing schedule. The result is a tool for dose precision, not a judgment of whether the patient did something wrong. When a level is unexpected, the safest response is to reconstruct the timing, review changes, and repeat or adjust under medical guidance.
References
- Tacrolimus 2024 (Review)
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP3A5 Genotype and Tacrolimus Dosing 2015 (Guideline)
- KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary 2009 (Guideline)
- Tacrolimus, Blood 2024 (Laboratory Test Guidance)
- PROGRAF (tacrolimus) capsules, for oral use; PROGRAF (tacrolimus) injection, for intravenous use; PROGRAF Granules (tacrolimus for oral suspension) 2022 (Prescribing Information)
Disclaimer
Tacrolimus dosing should be managed by a transplant specialist or prescribing clinician. The ranges in this article are general examples, not personal targets, and a person’s correct trough goal may be higher or lower based on organ type, time since transplant, rejection risk, infection risk, and other medicines. Seek urgent medical advice for severe neurologic symptoms, chest pain, very high potassium, sharply worsening kidney function, severe diarrhea or vomiting, or signs of serious infection.
